Brinker Capital Investments’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Brinker Capital Investments’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,746	Closed	-$213K	–	2274
2025 Q4	$213K	Buy	+1,746	New	+$200K	﹤0.01%	1993
2018 Q2	–	Sell	-143	Closed	-$13K	–	654
2018 Q1	$13K	Buy	+143	New	+$13.1K	﹤0.01%	445
2017 Q4	–	Sell	-23,000	Closed	-$1.99M	–	618
2017 Q3	$1.99M	Hold	23,000	–	–	0.07%	158
2017 Q2	$1.77M	Hold	23,000	–	–	0.07%	166
2017 Q1	$1.59M	Buy	23,000 +4,000	+21%	+$269K	0.07%	165
2016 Q4	$1.13M	Buy	19,000 +8,000	+73%	+$494K	0.05%	181
2016 Q3	$729K	Buy	+11,000	New	+$680K	0.03%	196
2013 Q3	–	Sell	-10,200	Closed	-$354K	–	399
2013 Q2	$354K	Buy	+10,200	New	+$358K	0.01%	223

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Brinker Capital Investments's XBI Position: Q1 2026 in Review

Brinker Capital Investments sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 1,746 shares — an estimated $213K sold.

Brinker Capital Investments first reported a position in XBI in Q2 2013 and held it in 8 quarters. The position peaked at $1.99M in Q3 2017. 816 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Brinker Capital Investments reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
Brinker Capital Investments sold 1,746 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $213K.
Brinker Capital Investments first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and held it in 8 quarters.
Brinker Capital Investments's State Street SPDR S&P Biotech ETF position peaked at $1.99M in Q3 2017.
816 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Brinker Capital Investments's 13F filing for Q1 2026, filed 13 May 2026.